Big Pharma invests in research for new antibiotics ($2bn)

Big pharma keeps investing in research for new antibiotics to fight drug-resistant infections. A recent survey by the International Federation of Pharmaceutical Manufacturers has revealed that 22 international drugmakers–including AstraZeneca, GSK and MSD–invested a total of over $2bn in research in 2016, which corresponds to approximately four times the amount invested by Government bodies or other non-profit entities. The firms focusing on this business have recently created a consortium called AMR Alliance, which comprises 100 companies and industry associations. The research for new antibiotics is among the priorities suggested by the World Health Organization, which has estimated that a minimum of 700,000 people are killed every year by infections that could be treated with better antibiotics. This figure is likely to reach 10m before 2050.
(Source: IFPMA)